Trex Bio

Biotech · Private

Antibody engineering platform for TNF superfamily inhibitor therapeutics

trexbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
1 granted · 7 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2496Semnur Pharmaceuticals, Inc.—$6.0M
2497b3 bio, inc.—$5.7M
2498DUET BIOSYSTEMS, INC——
2499Trex Bio——
2500Emergent BioSolutions—$48M
2501ARTELO BIOSCIENCES, INC.—$33M
2502Celmatix Inc.—$20M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 8
  • Tnf-alpha Variant Fusion Moleculesapplication
  • Tnf-alpha Variant Fusion Moleculesgranted
  • Anti-human LAIR1 Antibodiesapplication
  • Tnf-alpha Variant Fusion Moleculesapplication
  • Tnf-alpha Variant Fusion Moleculesapplication
  • Antibody-based Depletion Of IL1R2-POSITIVE Cellsapplication
  • Anti-human LAIR1 Antibodiesapplication
  • Antibody-based Depletion Of IL1R2-POSITIVE Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.